

WHAT IS CLAIMED IS:

1. A method for neutralizing the anti-coagulant effect of heparin comprising administering to a subject an effective amount of a heparin binding BPI protein product.
- 5 2. A method of inhibiting angiogenesis comprising administering to a subject an amount of a BPI protein product effective to inhibit angiogenesis.
3. A method for neutralizing the anti-coagulant effect of heparin  
10 in a fluid sample comprising contacting said sample with an effective amount of heparin binding BPI protein product.
4. The method of claim 2 wherein the angiogenesis inhibited is associated with ocular retinopathy.
- 15 5. A method for inhibiting endothelial cell proliferation comprising administering to a subject an amount of a BPI protein product effective to inhibit proliferation.
- 20 6. A method of treating endometriosis comprising administering an amount of BPI to the endometrium effective to inhibit endothelial cell proliferation.
7. A method for contraception comprising administering to a  
25 subject an amount of a BPI protein product to the uterine lining effective to prevent endothelial cell proliferation associated with implantation of a fertilized ovum.
8. A method for inhibiting malignant tumor cell proliferation comprising administering to a subject an amount of a BPI protein product effective  
30 to inhibit proliferation.

9. The method of claim 8 wherein the malignant tumor is Kaposi's sarcoma.

10. A method for treating a chronic inflammatory disease state  
5 comprising administering to a subject an amount of a BPI protein product effective to reduce inflammation.

11. The method of claim 10 wherein the chronic inflammatory  
disease is arthritis.

10

12. The method of claim 11 wherein the arthritic inflammatory  
disease state is rheumatoid arthritis.

13. The method of claim 11 wherein the arthritic inflammatory  
15 disease state treated is reactive arthritis.

14. The method of claims 1, 2, 5, 6, 7, 8 and 10 wherein the BPI  
protein product is a 23-25 kD amino-terminal fragment of bactericidal/permeability-  
increasing protein.

20

15. A method of inhibiting angiogenesis comprising administering  
to a subject an amount of a BPI protein product effective to inhibit angiogenesis.

16. The method of claim 15 wherein the angiogenesis inhibited is  
25 associated with ocular retinopathy.

17. A method for inhibiting endothelial cell proliferation  
comprising administering to a subject an amount of a bactericidal/permeability  
increasing (BPI) protein product effective to inhibit proliferation of endothelial  
30 cells.

5

10

15

22. The method of claim 17 wherein the BPI protein product is an approximately 21 to 25 kD amino-terminal fragment of BPI protein.